{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T01:21:08Z","timestamp":1781659268482,"version":"3.54.5"},"reference-count":49,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T00:00:00Z","timestamp":1762732800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Acromegaly is a rare endocrine disorder characterized by chronic excess growth hormone (GH) and elevated insulin-like growth factor-1 (IGF-1), which are known to have mitogenic and anti-apoptotic effects on breast tissue. While an increased risk of several malignancies has been observed in patients with acromegaly, the relationship between acromegaly and breast cancer remains unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To systematically evaluate the incidence and prevalence of breast cancer in patients with acromegaly and assess whether a consistent oncologic risk exists in this population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We systematically searched PubMed, EMBASE, and Web of Science from inception through early 2025 for studies reporting breast cancer in acromegaly. Citation tracking identified additional reports. After screening, 24 studies (&amp;gt;17,000 patients) were included, with data on cancer frequency, timing, and GH\/IGF-1 levels extracted for analysis. From a subset of these studies reporting standardized incidence ratios (SIR) with 95% confidence intervals (CIs), a random-effects meta-analysis was performed to generate a pooled SIR, accounting for between-study heterogeneity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>This systematic review of 24 studies with diverse designs, encompassing 17,413 patients with acromegaly, found breast cancer prevalence ranging from 0.42% to 5.85%. Several studies reported elevated GH and IGF-1 levels at any cancer diagnosis, but methodological heterogeneity limited conclusions on dose\u2013response or temporal associations. Ten studies reported SIRs with 95% CIs and were included in the pooled analysis. The pooled SIR for breast cancer among patients with acromegaly was 1.20 (95% CI: 0.94\u20131.54), with moderate heterogeneity (I\u00b2 = 58%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Although there is a strong biological rationale for a link between GH\/IGF-1 excess and breast cancer, current clinical studies have not shown a clear or consistently increased risk in patients with acromegaly. The mixed results likely reflect issues such as surveillance bias, differences in study designs, and limited adjustment for confounders. For now, breast cancer screening in this population should generally follow the same guidelines as the general population, with perhaps closer attention in patients who have poorly controlled disease. Moving forward, well-designed prospective studies that track cancer outcomes in relation to biochemical disease activity and control will be key to answering this question.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fendo.2025.1696291","type":"journal-article","created":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T05:18:36Z","timestamp":1762751916000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Acromegaly and breast cancer risk: evidence from a systematic review and meta-analysis"],"prefix":"10.3389","volume":"16","author":[{"given":"Hee Christy","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shruti N.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Koo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caitlin","family":"Plovnick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nidhi","family":"Agrawal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,11,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.85.1.6318","article-title":"Systemic hypertension and impaired glucose tolerance are independently correlated to the severity of the acromegalic cardiomyopathy","volume":"85","author":"Colao","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1210\/er.2018-00166","article-title":"Growth hormone\u2019s links to cancer","volume":"40","author":"Boguszewski","year":"2019","journal-title":"Endocr Rev"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.944s.11.2","article-title":"Insulin-like growth factor-I and breast cancer therapy","volume":"11","author":"Ibrahim","year":"2009","journal-title":"Clin Cancer Res"},{"key":"B4","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1210\/er.2008-0022","article-title":"Growth hormone and insulin-like growth factor-I in the transition from normal mammary development to preneoplastic mammary lesions","volume":"30","author":"Kleinberg","year":"2009","journal-title":"Endocr Rev"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1210\/en.2012-2208","article-title":"Growth hormone potentiates 17\u03b2-estradiol-dependent breast cancer cell proliferation independently of IGF-I receptor signaling","volume":"154","author":"Felice","year":"2013","journal-title":"Endocrinology"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexcr.2023.113862","article-title":"Insulin promotes growth in breast cancer cells through the type I IGF receptor in insulin receptor-deficient cells","volume":"434","author":"Monteiro","year":"2024","journal-title":"Exp Cell Res"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.10862","article-title":"IGF-1R inhibition sensitizes breast cancer cells to ATR inhibitor and cisplatin","volume":"7","author":"O\u2019Flanagan","year":"2016","journal-title":"Oncotarget"},{"key":"B8","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/s13058-019-1162-8","article-title":"Relationship of circulating IGF-I and binding proteins 1\u20137 with mammographic density among women undergoing breast biopsy","volume":"21","author":"Hada","year":"2019","journal-title":"Breast Cancer Res"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0285335","article-title":"Risk of cancer in acromegaly patients: an updated meta-analysis and systematic review","volume":"18","author":"Xiao","year":"2023","journal-title":"PLoS One"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2017-02457","article-title":"Cancer incidence in patients with acromegaly: a cohort study and meta-analysis","volume":"103","author":"Dal","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgab560","article-title":"Incidence of benign and Malignant tumors in acromegaly: a nationwide population-based study","volume":"106","author":"Esposito","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2015-2372","article-title":"The incidence of cancer among acromegaly patients: results from the German Acromegaly Registry","volume":"100","author":"Petroff","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-022-03082-z","article-title":"Cancer prevalence and screening in acromegaly: a single-center experience","volume":"77","author":"Durmu\u015f","year":"2022","journal-title":"Endocrine"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.4158\/EP-2020-0398","article-title":"Prevalence of cancer and its relation to disease activity in acromegaly: two centers\u2019 experience","volume":"27","author":"Ucan","year":"2021","journal-title":"Endocr Pract"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1159\/000505332","article-title":"Natural history of acromegaly: incidences, re-operations, cancers, and mortality in a national cohort","volume":"110","author":"Wu","year":"2020","journal-title":"Neuroendocrinology"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1210\/jc.83.8.2730","article-title":"Mortality and cancer incidence in acromegaly: a retrospective cohort study","volume":"83","author":"Orme","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2002-020973","article-title":"Increased risk of acromegaly and pituitary tumors in patients with thyroid cancer","volume":"87","author":"Baris","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgae469","article-title":"Prospective, longitudinal study of cancer predictors and rates in a NYC cohort of 598 patients with acromegaly","volume":"110","author":"Freda","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1530\/endoabs.41.EP890","article-title":"High incidence of thyroid cancer among patients with acromegaly","volume":"21","author":"Kaldrymidis","year":"2016","journal-title":"J BUON"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-010-0224-9","article-title":"Thyroid cancer is the most common cancer associated with acromegaly","volume":"13","author":"Gullu","year":"2010","journal-title":"Pituitary"},{"key":"B21","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1507\/endocrj.K07E010","article-title":"Prevalence of benign and Malignant tumors in acromegaly at a single institute","volume":"55","author":"Kurimoto","year":"2008","journal-title":"Endocr J"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgz315","article-title":"Clinical MEN-1 among a large cohort of patients with acromegaly","volume":"105","author":"Nachtigall","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2265.1998.00536.x","article-title":"Increased incidence of neoplasia in patients with pituitary adenomas","volume":"49","author":"Popovic","year":"1998","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1530\/eje.0.1510439","article-title":"Epidemiology, clinical characteristics, outcome, morbidity, and mortality in acromegaly: Spanish Acromegaly Registry","volume":"151","author":"Mestron","year":"2004","journal-title":"Eur J Endocrinol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/s11102-013-0501-5","article-title":"Increased thyroid cancer risk in acromegaly","volume":"17","author":"Dagdelen","year":"2014","journal-title":"Pituitary"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2265.1997.2561053.x","article-title":"Increased breast cancer incidence in acromegaly","volume":"47","author":"Cheung","year":"1997","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-020-02560-7","article-title":"Breast findings detected through screening in patients with acromegaly","volume":"72","author":"Akhanli","year":"2021","journal-title":"Endocrine"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(195701\/02)10:1<100::AID-CNCR2820100113>3.0.CO;2-V","article-title":"Occurrence of cancer in acromegaly and in hypopituitarism","volume":"10","author":"Mustacchi","year":"1957","journal-title":"Cancer"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgz317","article-title":"Risk for acromegaly-related comorbidities by sex in Korean acromegaly","volume":"105","author":"Park","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-016-0565-y","article-title":"Risk of Malignant neoplasms in acromegaly: a case\u2013control study","volume":"40","author":"Wolinski","year":"2017","journal-title":"J Endocrinol Invest"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1530\/EC-19-0332","article-title":"Acromegaly treatment with somatostatin analogues: a real-life study in Italy","volume":"8","author":"Terzolo","year":"2019","journal-title":"Endocr Connect"},{"key":"B32","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1007\/s11102-021-01198-9","article-title":"Prevalence of comorbidities and concomitant medication use in acromegaly: analysis of real-world data from the United States","volume":"25","author":"Fleseriu","year":"2022","journal-title":"Pituitary"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-16-1064","article-title":"Changes in the management and comorbidities of acromegaly over three decades: the French Acromegaly Registry","volume":"176","author":"Maione","year":"2017","journal-title":"Eur J Endocrinol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-16-0106","article-title":"Mortality in acromegaly: a 20-year follow-up study","volume":"23","author":"Ritvonen","year":"2016","journal-title":"Endocr Relat Cancer"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.02.007","article-title":"Insulin-like growth factor-1, insulin-like growth factor-binding protein-3, and breast cancer risk: observational and Mendelian randomization analyses with ~430\u2013000 women","volume":"31","author":"Murphy","year":"2020","journal-title":"Ann Oncol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s40842-020-00108-7","article-title":"Acromegaly and thyroid cancer: analysis of evolution in a series of patients","volume":"6","author":"Danilowicz","year":"2020","journal-title":"Clin Diabetes Endocrinol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1111\/j.1365-2265.1987.tb00814.x","article-title":"Acromegaly","volume":"26","author":"Nabarro","year":"1987","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-21-1070","article-title":"Associations between endogenous hormones (IGF-1 among others) and risk of invasive breast cancer in pre- and postmenopausal women in UK Biobank","volume":"81","author":"Tin","year":"2021","journal-title":"Cancer Res UK Biobank Study"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(10)70095-4","article-title":"Insulin-like growth factor 1 (IGF1), IGF binding protein 3 (IGFBP3), and breast cancer risk: pooled individual data analysis of 17 prospective studies","volume":"11","author":"Key","year":"2010","journal-title":"Lancet Oncol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-20-0832","article-title":"Circulating insulin-like growth factor-1 and risk of total and 19 site-specific cancers: cohort study analyses from the UK Biobank","volume":"29","author":"Qian","year":"2020","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.28589","article-title":"Insulin-like growth factor I and risk of breast cancer by age and hormone receptor status: a prospective study within the EPIC cohort","volume":"134","author":"Kaaks","year":"2014","journal-title":"Int J Cancer"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyad1234","article-title":"IGF-1 and risk of morbidity and mortality from cancer, cardiovascular diseases, and all causes in EPIC-Heidelberg: a case-cohort study","volume":"108","author":"Mukama","year":"2023","journal-title":"Int J Epidemiol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgad010","article-title":"Cancer incidence and mortality in a nationwide cohort of patients with acromegaly in Sweden","volume":"108","author":"Mukama","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-20-0019","article-title":"Prolonged diagnostic delay in acromegaly is associated with increased morbidity and mortality","volume":"182","author":"Esposito","year":"2020","journal-title":"Eur J Endocrinol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-16-0117","article-title":"Acromegaly incidence, prevalence, complications and long-term prognosis: a nationwide cohort study","volume":"175","author":"Dal","year":"2016","journal-title":"Eur J Endocrinol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/j.endonu.2013.03.008","article-title":"Diabetes and acromegaly","volume":"60","author":"Iglesias","year":"2013","journal-title":"Endocrinol Nutr"},{"key":"B48","first-page":"29","article-title":"Cancer prevalence in acromegalic patients from a tertiary centre: correlation with tumor size, duration or control","volume":"61","author":"Baldys-Waligorska","year":"2010","journal-title":"Endokrynol Pol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/152.10.950","article-title":"Cumulative risk of breast cancer to age 70 by risk factor status: Nurses\u2019 Health Study","volume":"152","author":"Colditz","year":"2000","journal-title":"Am J Epidemiol"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1696291\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T05:18:37Z","timestamp":1762751917000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1696291\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,10]]},"references-count":49,"alternative-id":["10.3389\/fendo.2025.1696291"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2025.1696291","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,10]]},"article-number":"1696291"}}